Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition. American Psychiatric Association; Arlington, VA: 2013
   Google Scholar
• Warikoo N, Faraone SV. Background, clinical features and treatment of attention deficit hyperactivity disorder in children. Expert Opin Pharmacother 2013;14:1885-906
   PubMed Web of Science ®Google Scholar
• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164(6):942-8
   PubMed Web of Science ®Google Scholar
• Rizzo R, Curatolo P, Gulisano M, et al. Disentangling the effects of Tourette syndrome and attention deficit hyperactivity disorder on cognitive and behavioral phenotypes. Brain Dev 2007;29:413-20
   PubMed Web of Science ®Google Scholar
• Cortese S. The neurobiology and genetics of attention-deficit/hyperactivity disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol 2012;16:422-33
   PubMed Web of Science ®Google Scholar
• Curatolo P, Paloscia C, D’Agati E, et al. The neurobiology of attention deficit/hyperactivity disorder. Eur J Paediatr Neurol 2009;13:299-304
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Rubia K, Rossi G, et al. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry 2012;169(3):264-72
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav 2011;99:211-16
   PubMed Web of Science ®Google Scholar
• Seixas M, Weiss M, Müller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol 2012;26(6):753-65
   PubMed Web of Science ®Google Scholar
• Jensen PS, Garcia JA, Glied S, et al. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry 2005;162(9):1628-36
   PubMed Web of Science ®Google Scholar
• Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Steeves T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011(4):CD007990
   Google Scholar
• MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56(12):1073-86
   PubMed Web of Science ®Google Scholar
• Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128(5):1007-22
   PubMed Web of Science ®Google Scholar
• Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009;23:21-31
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Jin LE. Molecular influences on working memory circuits in dorsolateral prefrontal cortex. Prog Mol Biol Transl Sci 2014;122:211-31
   Google Scholar
• Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007;129(2):397-410
   PubMed Web of Science ®Google Scholar
• Carr DB, Andrews GD, Glen WB, Lavin A. Alpha2-noradrenergic receptors activation enhances excitability and synaptic integration in rat prefrontal cortex pyramidal neurons via inhibition of HCN currents. J Physiol 2007;584(2):437-50
   Google Scholar
• Ren WW, Liu Y, Li BM. Stimulation of α(2A)-adrenoreceptors promotes the maturation of dendritic spines in cultured neurons of the medial prefrontal cortex. Mol Cell Neurosci 2012;49(2):205-16
   Google Scholar
• Franowicz JS, Kessler LE, Borja CM, et al. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci 2002;22(19):8771-7
   Google Scholar
• Faraone SV, McBurnett K, Sallee FR, et al. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents. Clin Ther 2013;35(11):1778-93
   PubMed Web of Science ®Google Scholar
• Carchman SH, Crowe JTJr, Wright GJ. The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. J Clin Pharmacol 1987;27(10):762-7
   Google Scholar
• Clement B, Demesmaeker M. Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim) 1997;330(9-10):303-6
   Google Scholar
• Intuniv [package insert]. Shire Pharmaceuticals, Inc; Wayne, PA: 2011
   Google Scholar
• Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy 2007;27(9):1253-62
   PubMed Web of Science ®Google Scholar
• Swearingen D, Pennick M, Shojaei A, et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther 2007;29(4):617-25
   Google Scholar
• Kisicki JC, Fiske K, Lyne A. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Clin Ther 2007;29(9):1967-79
   PubMed Web of Science ®Google Scholar
• Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158(7):1067-74
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008;121(1):73-84
   PubMed Web of Science ®Google Scholar
• Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48(2):155-65
   PubMed Web of Science ®Google Scholar
• Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010;24(9):755-68
   PubMed Web of Science ®Google Scholar
• Kollins SH, López FA, Vince BD, et al. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011;21(2):111-20
   PubMed Web of Science ®Google Scholar
• Newcorn JH, Stein MA, Childress AC, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry 2013;52(9):921-30
   PubMed Web of Science ®Google Scholar
• Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl. 2008. Available from: https://clinicaltrials.gov/ct2/show/NCT01081132
   Google Scholar
• Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 2014;53(2):153-73
   PubMed Web of Science ®Google Scholar
• Ruggiero S, Clavenna A, Reale L, et al. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2014;24(10):1578-90
   Google Scholar
• Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012;51(1):74-85
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed R, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008;13(12):1047-55
   PubMed Web of Science ®Google Scholar
• Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19(3):215-26
   PubMed Web of Science ®Google Scholar